BG
Bahl & Gaynor Portfolio holdings
AUM
$19.8B
1-Year Return
17.27%
This Quarter Return
+0.93%
1 Year Return
+17.27%
3 Year Return
+58.16%
5 Year Return
+110.76%
10 Year Return
+270.98%
AUM
$18.6B
AUM Growth
+$2.56B
(+16%)
Cap. Flow
+$2.55B
Cap. Flow
% of AUM
13.74%
Top 10 Holdings %
Top 10 Hldgs %
30.44%
Holding
344
New
5
Increased
153
Reduced
150
Closed
6
Top Buys
| 1 |
Travelers Companies
TRV
|
$119M |
| 2 |
AbbVie
ABBV
|
$115M |
| 3 |
Prologis
PLD
|
$112M |
| 4 |
Lockheed Martin
LMT
|
$106M |
| 5 |
RTX Corp
RTX
|
$103M |
Top Sells
| 1 |
Blackrock
BLK
|
$123M |
| 2 |
American Tower
AMT
|
$84.4M |
| 3 |
Fidelity National Information Services
FIS
|
$71.3M |
| 4 |
Medtronic
MDT
|
$49.4M |
| 5 |
Best Buy
BBY
|
$47M |
Sector Composition
| 1 | Technology | 21.01% |
| 2 | Healthcare | 14.45% |
| 3 | Financials | 12.75% |
| 4 | Consumer Staples | 12.05% |
| 5 | Industrials | 11.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
326
Synovus
SNV
$7.16B
| $212K | ﹤0.01% |
6,874
| – | – |
|
327
Black Stone Minerals
BSM
$2.5B
| $212K | ﹤0.01% |
+13,500
| New | +$212K |
|
328
Yum! Brands
YUM
$40.7B
| $212K | ﹤0.01% |
1,602
-38
| -2% | -$5.02K |
|
329
Elevance Health
ELV
$69.5B
| $207K | ﹤0.01% |
450
+8
| +2% | +$3.68K |
|
330
Concentrix
CNXC
$3.3B
| $203K | ﹤0.01% |
1,672
| – | – |
|
331
Kimbell Royalty Partners
KRP
$1.25B
| $190K | ﹤0.01% |
12,500
| – | – |
|
|
EFC
332
Ellington Financial
EFC
$1.39B
| $153K | ﹤0.01% |
12,500
| – | – |
|
333
Plug Power
PLUG
$1.69B
| $124K | ﹤0.01% |
10,573
| – | – |
|
334
Nokia
NOK
$24.7B
| $108K | ﹤0.01% |
21,900
| – | – |
|
335
Onconetix
ONCO
$4.22M
| $13K | ﹤0.01% |
4
| – | – |
|
336
Verisk Analytics
VRSK
$37.9B
| – | – |
-1,407
| Closed | -$248K |
|
337
CoStar Group
CSGP
$38.4B
| – | – |
-3,060
| Closed | -$236K |
|
338
Dollar General
DG
$23.7B
| – | – |
-946
| Closed | -$233K |
|
339
DexCom
DXCM
$31B
| – | – |
-1,853
| Closed | -$210K |
|
340
RB Global
RBA
$21.2B
| – | – |
-37,443
| Closed | -$2.17M |
|
341
Sarepta Therapeutics
SRPT
$1.9B
| – | – |
-1,597
| Closed | -$207K |
|